Symptom burden at the end-of-life for neuroendocrine tumors: an analysis of 2,579 prospectively collected patient-reported outcomes

Speaking of SurgOnc

English - May 12, 2020 05:00 - 7 minutes - 8.55 MB - ★★★★★ - 6 ratings
Natural Sciences Science education globalcancersurgery research surgicaloncology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Germline Genetic Testing: What the Breast Surgeon Needs to Know

Next Episode: Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility

Rick Greene, MD and Julie Hallet, MD discuss the moderate-to-severe symptoms observed to steeply increase as death nears for patients with neuroendocrine tumors (NETs), which highlight an opportunity for improved management.

Dr. Hallet is author of, “Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes.”

Dr. Hallet is Assistant Professor, Surgical Oncology, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Canada.